Oncotarget

Priority Research Papers:

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS

Mehrad Tavallai, Laurence Booth, Jane L. Roberts, William P. McGuire, Andrew Poklepovic and Paul Dent _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:17290-17300. https://doi.org/10.18632/oncotarget.8039

Metrics: PDF 1162 views  |   HTML 1500 views  |   ?  


Abstract

Mehrad Tavallai1, Laurence Booth1, Jane L. Roberts1, William P. McGuire2, Andrew Poklepovic2 and Paul Dent1

1 Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA

2 Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA

Correspondence to:

Paul Dent, email:

Keywords: ruxolitinib, JAK-STAT, DMF, tecfidera, ROS

Received: January 28, 2016 Accepted: February 29, 2016 Published: March 15, 2016

Abstract

We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF). Ruxolitinib interacted with MMF to kill brain, breast, lung and ovarian cancer cells, and enhanced the lethality of standard of care therapies such as paclitaxel and temozolomide. MMF also interacted with other FDA approved drugs to kill tumor cells including Celebrex® and Gilenya®. The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage. Expression of activated forms of STAT3, MEK1 or AKT each significantly reduced drug combination lethality; prevented BAD S112 S136 dephosphorylation and decreased BIM expression; and preserved TRX, SOD2, MCL-1 and BCL-XL expression. The drug combination increased the levels of reactive oxygen species in cells, and over-expression of TRX or SOD2 prevented drug combination tumor cell killing. Over-expression of BCL-XL or knock down of BAX, BIM, BAD or apoptosis inducing factor (AIF) protected tumor cells. The drug combination increased AIF : HSP70 co-localization in the cytosol but this event did not prevent AIF : eIF3A association in the nucleus.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8039